Structural mechanism for STI-571 inhibition of abelson tyrosine kinase - PubMed (original) (raw)
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
T Schindler et al. Science. 2000.
Abstract
The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML). A small-molecule inhibitor of Abl (STI-571) is effective in the treatment of CML. We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571. Critical to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated. The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases. These results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.
Comment in
- Molecular biology. Cancer fighter's modus operandi revealed.
Marx J. Marx J. Science. 2000 Sep 15;289(5486):1857-9. doi: 10.1126/science.289.5486.1857. Science. 2000. PMID: 11012350
Similar articles
- Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Nagar B, et al. Cancer Res. 2002 Aug 1;62(15):4236-43. Cancer Res. 2002. PMID: 12154025 - Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. Nagar B, et al. Cell. 2003 Mar 21;112(6):859-71. doi: 10.1016/s0092-8674(03)00194-6. Cell. 2003. PMID: 12654251 - c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
Nagar B. Nagar B. J Nutr. 2007 Jun;137(6 Suppl 1):1518S-1523S; discussion 1548S. doi: 10.1093/jn/137.6.1518S. J Nutr. 2007. PMID: 17513418 - STI-571: an anticancer protein-tyrosine kinase inhibitor.
Roskoski R Jr. Roskoski R Jr. Biochem Biophys Res Commun. 2003 Oct 3;309(4):709-17. doi: 10.1016/j.bbrc.2003.08.055. Biochem Biophys Res Commun. 2003. PMID: 13679030 Review. - [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M, Toga W. Nakajima M, et al. Nihon Yakurigaku Zasshi. 2003 Dec;122(6):482-90. doi: 10.1254/fpj.122.482. Nihon Yakurigaku Zasshi. 2003. PMID: 14639002 Review. Japanese.
Cited by
- A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures.
Herrington NB, Li YC, Stein D, Pandey G, Schlessinger A. Herrington NB, et al. PLoS Comput Biol. 2024 Jul 24;20(7):e1012302. doi: 10.1371/journal.pcbi.1012302. eCollection 2024 Jul. PLoS Comput Biol. 2024. PMID: 39046952 Free PMC article. - The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding.
Felder ER, Badari A, Disingrini T, Mantegani S, Orrenius C, Avanzi N, Isacchi A, Salom B. Felder ER, et al. Mol Divers. 2012 Feb;16(1):27-51. doi: 10.1007/s11030-012-9361-6. Epub 2012 Feb 15. Mol Divers. 2012. PMID: 22350112 - Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.
Herter-Sprie GS, Greulich H, Wong KK. Herter-Sprie GS, et al. Front Oncol. 2013 Apr 23;3:86. doi: 10.3389/fonc.2013.00086. eCollection 2013. Front Oncol. 2013. PMID: 23630663 Free PMC article. - Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases.
Meng Y, Lin YL, Roux B. Meng Y, et al. J Phys Chem B. 2015 Jan 29;119(4):1443-56. doi: 10.1021/jp511792a. Epub 2015 Jan 15. J Phys Chem B. 2015. PMID: 25548962 Free PMC article. - Structure, regulation, signaling, and targeting of abl kinases in cancer.
Hantschel O. Hantschel O. Genes Cancer. 2012 May;3(5-6):436-46. doi: 10.1177/1947601912458584. Genes Cancer. 2012. PMID: 23226581 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous